This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
The Zacks Analyst Blog Highlights Procter & Gamble, Coca-Cola, The Progressive, Zoetis and Palo Alto Networks
by Zacks Equity Research
Procter & Gamble, Coca-Cola, The Progressive, Zoetis and Palo Alto Networks are part of the Zacks top Analyst Blog.
Top Stock Reports for Procter & Gamble, Coca-Cola & Progressive
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), The Coca-Cola Company (KO) and The Progressive (PGR).
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
by Zacks Equity Research
Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.
Zoetis (ZTS) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of -2.42% and 3.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More
by Kinjel Shah
Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.
Why Zoetis (ZTS) Might Surprise This Earnings Season
by Zacks Equity Research
Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.
Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Pet Industry Seems Recession-Proof: ETF & Stocks in Focus
by Sanghamitra Saha
American Pet Products Association, 70% of U.S. households own a pet, as quoted on Yahoo Finance. And Americans are splurging on their pets despite high inflation.
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
TAK vs. ZTS: Which Stock Is the Better Value Option?
TAK or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TAK vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Bank of America, Toyota Motor, AT&T, The Home Depot, Zoetis, and Occidental Petroleum
by Zacks Equity Research
Bank of America, Toyota Motor, AT&T, The Home Depot, Zoetis, and Occidental Petroleum are included in this Analyst Blog.
Top Stock Reports for Bank of America, Toyota Motor & AT&T
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Toyota Motor Corporation (TM) and AT&T Inc. (T).
TAK vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
TAK vs. ZTS: Which Stock Is the Better Value Option?
Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.
Zoetis (ZTS) Misses Q2 Earnings Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of -1.64% and 1.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
TAK vs. ZTS: Which Stock Is the Better Value Option?
What's in the Cards for Bausch Health (BHC) Q2 Earnings?
by Zacks Equity Research
An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.39% and 14.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on top-line and bottom-line numbers when Viatris (VTRS) reports second-quarter results.
Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.